Sapphire Bomb
A Bomb Seeds hybrid marketed as a heavy, resinous cross of Blueberry and THC Bomb with a sweet-fuel aroma.
Sapphire Bomb is a Bomb Seeds catalog strain — essentially a Blueberry-leaning cross designed for commercial appeal. Breeder-reported THC numbers (around 20%) are marketing figures, not lab-verified population averages. There's no peer-reviewed data on this specific cultivar's chemistry or effects, and 'sapphire' refers to color and branding, not any unique compound. Treat everything below the lineage claim as breeder marketing plus grower anecdote, not established fact.
Overview
Sapphire Bomb is a commercial hybrid released by Bomb Seeds, a Dutch seed bank in the 'Bomb' line (THC Bomb, Berry Bomb, Atomic Bomb, etc.). It's pitched as a Blueberry-forward indica-leaning plant with a sweet, fruity, slightly fuel-tinged aroma and dense, resin-heavy flowers that sometimes throw purple-blue hues in cool finishes [1]. Like most catalog strains, nearly everything published about it — potency, yield, effects — comes from the breeder's own marketing copy rather than independent testing Weak / limited. It exists in both photoperiod and autoflowering formats, sold primarily through European seed retailers.
Chemistry: cannabinoids and terpenes
Bomb Seeds lists Sapphire Bomb at roughly 20% THC with negligible CBD [1]. No peer-reviewed chemotype study covers this cultivar specifically, and there is no public dataset of Certificate of Analysis results large enough to give a reliable population mean No data. In practice, THC in any given harvest will swing several percentage points based on phenotype, cure, and lab method [2].
The terpene profile is described in marketing copy as sweet berry with earthy undertones, which is loosely consistent with a myrcene- and pinene-leaning profile typical of Blueberry descendants Weak / limited. The idea that a specific terpene percentage (e.g. the widely repeated 'myrcene above 0.5% = couch-lock' claim) predicts effects is folklore, not established pharmacology [3] Disputed. Without a lab report on the exact seed lot you're buying, treat aroma descriptions as flavor guidance, not chemistry.
Reported effects
Grower and consumer reports describe Sapphire Bomb as producing a relaxed, body-heavy experience with a mellow head component — standard descriptors for a Blueberry-leaning hybrid [1] Anecdote. There are no clinical trials on Sapphire Bomb, and there won't be: cultivar-level clinical research on cannabis is essentially nonexistent, and effects vary far more with dose, route, tolerance, and set/setting than with strain name [4] Strong evidence.
The common indica-vs-sativa framing used to predict effects has been repeatedly criticized by researchers as unreliable; chemotype (cannabinoid + terpene profile) predicts effects better than lineage labels, and even that link is modest [5] Strong evidence. If a vendor tells you Sapphire Bomb will reliably do X for anxiety, sleep, or pain, that's a sales pitch, not evidence.
Lineage
Bomb Seeds describes Sapphire Bomb as a cross involving Blueberry and their own THC Bomb line [1]. The exact parent selections, generations, and any backcrossing are not publicly documented — this is normal for commercial seed banks, which rarely publish full pedigree records Weak / limited. Blueberry itself has a well-known but also partially contested history traced to DJ Short's work in the 1970s–80s, and 'Blueberry' sold today is often a redistributed or reworked line rather than the original [6] Disputed. Treat the lineage as directional (expect Blueberry-ish traits) rather than a precise genetic claim.
Cultivation basics
Reported grow characteristics from the breeder and grower forums [1] Anecdote:
- Flowering time: 8–9 weeks indoors; outdoor harvest late September to early October in the Northern Hemisphere.
- Structure: Medium height, bushy, responds well to topping and light training (LST/ScrOG).
- Yield: Breeder claims around 500–550 g/m² indoors under good conditions — a figure that assumes experienced growers, adequate light (typically 600W+ HPS or equivalent LED), and healthy substrate. Real-world yields are often lower.
- Climate: Prefers a stable indoor environment; can finish outdoors in temperate climates but appreciates dryness in late flower to avoid bud rot in dense colas.
- Difficulty: Generally considered beginner-friendly for a photoperiod hybrid; the autoflower version compresses the timeline to roughly 10–11 weeks seed-to-harvest.
As with any strain, phenotype variation from regular or feminized seed means individual plants can differ noticeably in aroma, potency, and yield.
Marketing vs. reality
A few things worth separating:
- The name. 'Sapphire' evokes blue color and rarity. It's branding. There is no sapphire-associated compound in cannabis, and blue/purple coloration comes from anthocyanins expressed under cool temperatures, not from any 'sapphire' genetics [7] Strong evidence.
- The potency figure. '20% THC' is a breeder ceiling estimate, not a lab-verified mean. Independent testing of retail cannabis routinely finds discrepancies between advertised and measured THC [2] Strong evidence.
- Predicted effects. Any claim that Sapphire Bomb specifically treats a medical condition is unsupported. Cannabis research operates at the compound level (THC, CBD, specific terpenes), not the strain-name level [4][5] Strong evidence.
- Lineage prestige. 'Blueberry cross' is a common selling point across dozens of modern hybrids; it does not guarantee the flavor or effect of DJ Short's original line [6] Disputed.
Bottom line: Sapphire Bomb is a competent, sweet-smelling commercial hybrid. That's a reasonable thing to buy. Just don't buy it expecting the marketing copy to be a spec sheet.
Sources
- Practitioner Bomb Seeds. Sapphire Bomb product page (breeder listing).
- Peer-reviewed Jikomes, N., & Zoorob, M. (2018). The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific Reports, 8, 4519.
- Peer-reviewed Russo, E. B. (2019). The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No 'Strain,' No Gain. Frontiers in Plant Science, 9, 1969.
- Peer-reviewed MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, 49, 12–19.
- Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE, 17(5), e0267498.
- Reported Bienenstock, D. (2016). 'The Legend of Blueberry: An Interview with DJ Short.' High Times.
- Peer-reviewed Andre, C. M., Hausman, J.-F., & Guerriero, G. (2016). Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers in Plant Science, 7, 19.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Myrcene — The most common monoterpene in cannabis, blamed and credited for a lot of things it probab...